Abstract
You have accessJournal of UrologyCME1 May 2022MP29-05 PROPENSITY-SCORE ANALYSIS COMPARING PERIOPERATIVE AND FUNCTIONAL OUTCOMES BETWEEN XPS 180 W PHOTOVAPORIZATION AND GREENLIGHT LASER ENUCLEATION OF THE PROSTATE: REASONS TO DISCARD VAPORIZATION AND MOVE TO ENUCLEATION Anis Gasmi, Zine-Eddine Khene, Sonia Guérin, Karim Bensalah, Benoit Peyronnet, Romain Mathieu, Morgan Rouprêt, Enrique Rijo, Benjamin Pradère, and Vincent Misrai Anis GasmiAnis Gasmi More articles by this author , Zine-Eddine KheneZine-Eddine Khene More articles by this author , Sonia GuérinSonia Guérin More articles by this author , Karim BensalahKarim Bensalah More articles by this author , Benoit PeyronnetBenoit Peyronnet More articles by this author , Romain MathieuRomain Mathieu More articles by this author , Morgan RouprêtMorgan Rouprêt More articles by this author , Enrique RijoEnrique Rijo More articles by this author , Benjamin PradèreBenjamin Pradère More articles by this author , and Vincent MisraiVincent Misrai More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002572.05AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: To compare the perioperative and functional outcomes between 180_W XPS GreenLight photoselective vaporization (PVP) and 532-nm GreenLight laser enucleation of the prostate (GreenLEP) in the surgical management of benign prostatic obstruction (BPO). METHODS: Retrospective review of a prospectively maintained international database of patients managed with GreenLight laser surgery (PVP or GreenLEP) was performed. To adjust for potential baseline confounders, propensity-score matching (PSM) was applied at a ratio of 1:1 to compare the perioperative and functional outcomes between the groups. RESULTS: A total of 2,420 patients were included. 1,491 (61.6%) underwent PVP and 929 (38.4%) underwent GreenLEP. Before PSM analysis, patients in the vaporization group were older (p < 0.001), had a lower PSA and prostate volume at baseline (p < 0.001). Using estimated propensity scores, 78 patients in the PVP group were matched 1:1 to the patients in the GreenLEP group. The incidence of overall postoperative complications was comparable between the two groups (19 vs. 16%, p = 0.06). However, after PSM, PVP was found to be associated with a higher rate of overall complications (33 vs. 11%, p = 0.001). At 3 months and at last follow-up the I-PSS, Qmax and PSA had similarly decreased in the two groups with a greater improvement in the GreenLEP group (all p < 0.05). CONCLUSIONS: PVP and GreenLEP are two efficient and safe techniques for treating BPO. However, PVP was associated with longer operative time and higher risk of reoperation on a midterm follow-up compared to GreenLEP. Source of Funding: None © 2022 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 207Issue Supplement 5May 2022Page: e471 Advertisement Copyright & Permissions© 2022 by American Urological Association Education and Research, Inc.MetricsAuthor Information Anis Gasmi More articles by this author Zine-Eddine Khene More articles by this author Sonia Guérin More articles by this author Karim Bensalah More articles by this author Benoit Peyronnet More articles by this author Romain Mathieu More articles by this author Morgan Rouprêt More articles by this author Enrique Rijo More articles by this author Benjamin Pradère More articles by this author Vincent Misrai More articles by this author Expand All Advertisement PDF DownloadLoading ...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have